Will Hemp CBD Industry Really Explode if the Hemp Bill is Passed - Seite 3

Aphria Inc. (NYSE:APHA) (TSX:APHA) and Rapid Dose Therapeutics (CSE:DOSE) recently announced that they have expanded the scope of their previously announced agreement (the "Agreement") expanding the territory where Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT's QuickStrip innovative, proprietary delivery technology for the cannabis market to Germany. " Germany is one of the most sought-after cannabis markets today, and Aphria continues to take a comprehensive approach to ensure a leading presence in the country as the opportunity evolves," said Jakob Ripshtein, President of Aphria. "Aphria is committed to bringing advanced products and innovations to cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip technology to the German market and offer a unique nutraceutical product that delivers a consistent dosage."

CV Sciences Inc. (OTCQB:CVSI) on Wednesday announced that its Chief Executive Officer Joseph Dowling will be participating as a panelist at The 2nd Annual Neuroscience Innovation Forum taking place on January 6, 2019 at the Marines' Memorial Club in San Francisco, California. The forum's target audience, include buy and sell-side analysts from investment banks and funds and partnering executives from pharma and medtech companies. Panels will focus on innovation in neurotechnology covering banking, device, diagnostics and software. The 2nd Annual Neuroscience Innovation Forum is hosted by Sachs Associates, a firm that has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. The forum will feature around 200 corporate representatives and over 25 company presentations by established public, private and emerging companies.

PotNetwork Holdings Inc. (OTCPK:POTN) recently announced the company and its wholly-owned subsidiary, Diamond CBD Inc., have begun planning how the Company will effectively bolster its corporate footprint in a market anticipated to see great changes based on recent legislative events. The $867 Billion Farm Bill includes a provision involving industrial hemp and its derivative, cannabidiol (CBD), effectively removing CBD from the Controlled Substances Act Scheduling and putting it under the supervision of the Department of Agriculture. Applauding the recent actions of both houses of Congress to effectively pass a farm bill with hemp provisions, analysts are optimistic, indicating that the landscape has never been more ready for Presidential follow through. The U.S. Senate voted overwhelmingly (with an 87 to 13 vote) to approve the bill. Being one step closer to redefining low-THC hemp as a legal plant, the doors of opportunity begin opening to new and better research, the production of more tailored premium quality formulations, and a strengthened economy benefiting from the legal interstate commerce of hemp and CBD products. With Presidential endorsement, a long-marginalized industry can quickly help revitalize the American economy.